CytoDyn (CytoDyn) Pre-Tax Income

: $-51.69 Mil (TTM As of Feb. 2024)

View and export this data going back to 2005. Start your Free Trial

Pretax income is the income that a company earns before paying income taxes. CytoDyn's pretax income for the three months ended in Feb. 2024 was $-11.92 Mil. Its pretax income for the trailing twelve months (TTM) ended in Feb. 2024 was $-51.69 Mil. CytoDyn's pretax margin was %.

During the past 13 years, CytoDyn's highest Pretax Margin was -79255.64%. The lowest was -79255.64%. And the median was -79255.64%.

CytoDyn Pre-Tax Income Historical Data

The historical data trend for CytoDyn's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Pre-Tax Income

Get a 7-Day Free Trial

-59.01

-139.94

-176.47

-210.82

-79.82

CytoDyn Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Pre-Tax Income	Get a 7-Day Free Trial															-13.70	-18.64	-11.57	-9.56	-11.92

Competitive Comparison

For the Biotechnology subindustry, CytoDyn's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn Pre-Tax Income Distribution

For the Biotechnology industry and Healthcare sector, CytoDyn's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where CytoDyn's Pre-Tax Income falls into.

CytoDyn Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

CytoDyn's Pretax Income for the fiscal year that ended in May. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-40.576	+	-8.75	+	-6.75	+	0	+	-23.748
	=	-79.82

CytoDyn's Pretax Income for the quarter that ended in Feb. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-3.414	+	-2.508	+	-1.56	+	0	+	-4.438
	=	-11.92

Pre-Tax Income for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.69 Mil.

CytoDyn (OTCPK:CYDY) Pre-Tax Income Explanation

CytoDyn's Pretax Margin for the quarter that ended in Feb. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-11.92	/	0
	=	%

During the past 13 years, CytoDyn's highest Pretax Margin was -79255.64%. The lowest was -79255.64%. And the median was -79255.64%.

CytoDyn Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of CytoDyn's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn (CytoDyn) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

296:Germany

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

Executives

Tyler Blok	officer: EVP of Legal Affairs	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes	director
Ryan Dunlap	director	310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman	officer: President	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor	officer: Chief Operating Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland	officer: CFO, Treasurer and Secretary	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660